Summary: This study determined the effectiveness of checkpoint inhibitors (ICIs) for the treatment of patients with non-small cell lung cancer (NSCLC) with uncommon histology (uNSCLC).
Summary: This case report describes a 64-year-old male smoker diagnosed with pulmonary large cell neuroendocrine carcinoma (LCNEC) treated with thoracoscopic radical surgery, postoperative chemotherapy with a double-drug regimen holding platinum, and then, bevacizumab, paclitaxel, and the PD-L1 checkpoint inhibitor nivolumab.
Summary: This study reported results for the use of adoptive cell therapy using zoledronate-expanded autologous V?9V?2 T-cells in patients with treatment-refractory non-small cell lung cancer (NSCLC).
Summary: The study researched the effects of SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma.
Summary: This study analyzed patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) for pericardial effusion.
Summary: This study evaluated the effectiveness and safety of osimertinib treatment used for T790 mutation-positive non-small cell lung cancer (NSCLC) patients.
Summary: The study researched the safety and effectiveness of bevacizumab with platinum-based chemotherapy for patients with advanced non-small-cell lung cancer.
Summary: In this study, researchers compared the effectiveness of docetaxel plus cisplatin versus paclitaxel plus carboplatin for the treatment of completely resected non-small cell lung cancer.
Summary: In this study, researchers evaluated the safety and effectiveness of osimertinib for the treatment of EGFR exon 20 mutation positive non-small cell lung cancer.